By enGenes Biotech…
Subscribe to Supplier
Subscribe to Supplier
enGenes returning to Swiss Biotech Day
Vienna, Austria: – Recombinant proteins specialist CDMO enGenes Biotech GmbH (enGenes) will return to the influential Swiss Biotech Day conference in Basel, at the heart of Switzerland’s thriving cluster of life science industries and research.
The enGenes team in Basel, led by Head of Business Development, Dr. Karl Hübler, will take part in Swiss Biotech Day’s many networking activities, including one-on-one partnering meetings and its Global Village that hosts delegations from all over the world.
Leading-edge technologies
Its networking campaign will emphasize the strategic importance to biotech producers of its leading-edge upstream and downstream process development technologies and advanced proprietary and biomolecule production platforms, such as enGenes-eXpress™, -eXtra™, for enhanced protein production by expression in E. coli or by secretion , as well as -eXcite™, technology for continuous biomolecule production, and -eXpand™, for site-specific incorporation of non-canonical amino acids (NCAAs).
Since its debut at the conference in 2023, enGenes has also become a leading player in development of continuous and sustainable biotech manufacturing through its participation in the ECOnti project.
Project partner
Once again, it will use the conference to connect with existing customers and leads to potential new partners.
CEO and co-founder Dr. Jürgen Mairhofer commented: “We have an exciting story to tell about the ways our technologies can transform the economics of a very wide range of biopharma and industrial biotech process development projects and how our auxiliary know-how in upstream- and downstream-processing of plasmid DNA can enable significant cost savings, when manufacturing viral vectors for example”.
“We can also talk about the progress the ECOnti consortium is making towards continuous biomolecule production in E. coli for reduced footprint microbial manufacturing, with the project now well on the way to developing a low ecological footprint manufacturing platform for continuous production of biotech products that features fully automated continuous upstream and downstream processes,” Dr. Mairhofer added.
About enGenes Biotech
enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading-edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of the current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.
enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes, including its proprietary enGenes -eXpress™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes -eXpress™ has been successfully applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.
enGenes Biotech offers development and manufacturing services tailored to the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.
Find out more at: https://www.engenes.cc
About Swiss Biotech Day 2025
The Swiss Biotech Day conference has become a leading annual event for the European biotechnology community, providing a forum for life sciences industry experts and professionals to network, discuss and explore trends and latest developments in R&D, manufacturing, data management, artificial intelligence and innovative financing.
Founded in 2013, the conference is built around the Annual General Assembly of the Swiss Biotech Association and now attracts more than 2,500 participants, including entrepreneurs, investors, researchers, analysts, political decision makers and industry stakeholders from around the world.
Swiss Biotech Day for 2025 extends over two days, May 5-6, again at the Basel Conference Center at the heart of the Swiss pharma and biotech cluster. The conference will feature a “Global Village” of round table discussions providing opportunities for cross-border investments, public-private partnerships, research and development collaborations and knowledge exchange, along with one-to-one networking.
The event is organized by the Swiss Biotech Association in partnership with BIOCOM AG, with further information at: https://swissbiotechday.ch
Resources
Click on Partnering with enGenes for further information.
Swiss Biotech Day conference sessions and discussion forums are attended by biotechnology industry leaders from all over the world.
Representing enGenes: Head of Business Development Dr. Karl Hübler.
Related Articles
